What is Resolution Therapeutics?
Resolution Therapeutics is a specialized biotechnology enterprise focused on the development of macrophage cell therapies designed to treat inflammatory organ disease. Originating from a strategic collaboration between the Centre for Regenerative Medicine at the University of Edinburgh and the Scottish National Blood Transfusion Service, the company operates at the intersection of academic research and commercial drug development. Its core technology platform utilizes the innate immune system's regenerative potential to modulate inflammatory responses, offering a novel therapeutic modality for conditions that have historically lacked effective interventions. Based on the Edinburgh Royal Infirmary Campus, the company maintains a strong link to its academic roots while scaling its manufacturing and clinical trial capabilities to meet the rigorous demands of the global pharmaceutical market.
How much funding has Resolution Therapeutics raised?
Resolution Therapeutics has raised a total of $119.4M across 2 funding rounds:
Series A
$36.1M
Series B
$83.3M
Series A (2020): $36.1M with participation from Syncona
Series B (2024): $83.3M led by Syncona
Key Investors in Resolution Therapeutics
Syncona
Syncona is a FTSE250 company dedicated to founding, building, and funding healthcare companies that aim to provide transformative treatments for patients facing significant unmet medical needs. The company manages a diversified portfolio of life science firms, including those in various clinical stages, from pre-clinical to late-stage development.
What's next for Resolution Therapeutics?
With the recent influx of capital, Resolution Therapeutics is poised to accelerate its clinical development programs and expand its internal research infrastructure. The strategic focus will likely shift toward optimizing the manufacturing processes for its macrophage-based products, ensuring scalability for future multi-center clinical trials. As the company navigates the complexities of regulatory approval and clinical efficacy testing, the continued backing from institutional partners will be critical in maintaining its competitive edge. Future milestones will center on demonstrating the safety and therapeutic durability of its lead candidates, potentially opening doors for strategic partnerships or licensing agreements with larger pharmaceutical entities looking to bolster their immunology portfolios. The company remains committed to its mission of transforming patient outcomes through innovative cellular therapies, with a clear roadmap for long-term value creation in the biotechnology sector.
See full Resolution Therapeutics company page
